Onkológia 4/2012

Overview of treatment of castration-resistant prostate cancer

Prostatic cancer is a very heterogenic disease. Initial treatment of metastatic disease is androgen deprivation therapy, however upon the time eventually all cases develop castrat resistent disease (CRCP). In CRPC the combination of docetaxel with prednison is considered to be the gold standard first line therapy with prolongation of overall survival. Until recently there was not standardly defined second line treatment. According to the international guidelines of today cabazitaxel and abirateron is recomended as second line therapy. The objective of this article is to present a review of the therapy of CRPC upon results from randomised phase III clinical trials.

Keywords: prostatic cancer, castrat resistant, androgen deprivation, chemotherapy, cabazitaxel, docetaxel, abirateron.